Selank Where to Buy: Withdrawn From the List, Still Sold

Selank where to buy has a short answer and a much longer explanation. The short answer is that one channel exists: research-chemical suppliers selling a freeze-dried vial labelled not for human consumption. The longer explanation is why every channel you would expect alongside it is missing, and what that absence should change about how you read a product page.

Start where a pharmacist would start. FDA sets out in plain terms when a state-licensed pharmacy may compound from a bulk drug substance. The substance has to comply with a United States Pharmacopeia or National Formulary monograph if one exists. If none exists, it has to be a component of an FDA-approved drug product. If neither is true, it has to appear on FDA's list of bulk drug substances that can be used in compounding, the 503A bulks list. The rule is on FDA's 503A bulk drug substances page, content current as of 14 May 2026.

Run Selank against those three conditions and it fails all three. There is no USP or NF monograph for it. No FDA-approved drug product contains it, because none has ever been approved. And it is not on the 503A bulks list. Three failures, and the compounding route closes. That is not an opinion; it is arithmetic on a public list.

This page ends at a supplier we earn a commission from, set out in our affiliate disclosure. It also names the tests that supplier's February certificate does not carry, because a standard only its author's pick can clear is not a standard.

Almost every page competing for this query reports Selank as sitting in FDA's category 2, sometimes described as banned from compounding. Check the source and that is not what it says today.

FDA's page on bulk substances that may present significant safety risks, content current as of 22 April 2026, carries two separate tables. One lists the substances currently in category 2 under the interim policies. Under section 503A, the pharmacy route that matters to a retail patient, that table holds six substances: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. Selank is not one of them.

The second table is headed bulk drug substances nominated but withdrawn, and FDA describes it in one sentence: this list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators. Selank acetate, which FDA names with its Russian development code as Selank acetate (TP-7), sits in that second table. So the accurate sequence is nominated, evaluated, placed in category 2, then withdrawn by whoever nominated it. It is not on a current category list at all.

A withdrawn nomination does not create a compounding route; the three-part test above still fails. What it changes is that the confident sentence you have read elsewhere, the one saying FDA banned Selank, describes a status the agency's own page no longer assigns to it.

One more detail closes the door for the foreseeable future. FDA has issued guidance stating that it does not intend to place bulk drug substances nominated on or after 7 January 2025 into these categories at all. The interim category system is no longer taking new entrants, so a re-nomination is not a realistic path back.

The entry for Selank on that same FDA page is two sentences, and they are the most useful two sentences anyone can hand you before you buy. FDA writes: "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans." The full page is here.

Read what that is and is not. It is not a finding that Selank harmed anyone; FDA says the opposite, that it lacks the information to know. It is a statement about manufacturing risk. Immunogenicity means the immune system reacting to what was injected, and the two named causes are aggregation, where molecules clump into structures the body reads as foreign, and the truncated and modified sequences that come out of synthesis alongside the target.

That converts into purchase criteria more directly than most regulatory language does. Peptide-related impurities are what a purity assay measures; aggregation and contamination are what endotoxin and sterility testing address. The honest reading is neither stop nor proceed. It is that the documentation attached to a specific batch is the only thing standing between the concern and you.

It also explains the company Selank keeps. The same withdrawn list holds BPC-157, MOTs-C, Semax, CJC-1295, ipamorelin, TB-500 and Melanotan II, worded almost identically. Our piece on why no clinician can write a BPC-157 script is the same mechanism on a different peptide.

In a prescription transaction the certificate is invisible to you: a manufacturer releases a batch against a specification, a pharmacist checks the label, and accountability sits with people who can be inspected. Here none of that exists, so the certificate is the entire quality record. The checklist further down sets out what it has to cover.

One distinction on it is worth expanding now, because it is the one FDA's language points at and the one routinely blurred. A sample can be 99 percent pure by HPLC and still carry bacterial cell-wall fragments in quantities that cause a febrile reaction, because a purity assay is not looking for them and will never report them.

Identity is worth a note too, because the number is easy to check. Selank is a synthetic heptapeptide, seven residues in the order threonine, lysine, proline, arginine, proline, glycine, proline. The first four are tuftsin, an immune peptide the body makes; the Pro-Gly-Pro tail slows enzymatic breakdown. Its formula is C33H57N11O9 and its molecular weight is 751.9, confirmable on PubChem entry CID 11765600. A mass spectrum that does not land near 751 is not Selank, whatever the label says.

Ascension Peptides is the supplier this page links, and it publishes a certificate rather than a purity claim. Here is what the document actually contains.

The certificate was issued by MZ Biolabs in Tucson, Arizona, for lot 29-01260229, with an analysis date of 7 February 2026 and a report date of 13 February. Purity is 99.32 percent by HPLC with ultraviolet detection, and the chromatogram is reproduced, showing the Selank peak at 7.13 minutes and one minor peak at 6.36 minutes accounting for 0.68 percent. Identity is confirmed by mass spectrometry: expected monoisotopic mass 751.43 daltons, measured 751.47. That is the number from PubChem, matched to within four hundredths of a dalton.

Then the line that is genuinely unusual. The certificate reports a measured quantity of 12.29 mg per vial against a 10 mg label. The vial is overfilled by roughly 23 percent, and the vendor published the figure rather than rounding it to the label. Most suppliers do not quantify contents at all. Treat it as creditable and as lot specific: it describes lot 29-01260229 and is not a promise about the vial that reaches you.

And then the limit of that document. There is no bacterial endotoxin test on it, no LAL assay, no pyrogen test, no sterility or microbial screen, and no heavy metals panel. Identity and purity are covered thoroughly. The contamination question FDA named is not addressed on this February lot. You can confirm both halves of that in about a minute by opening the Selank certificate for lot 29-01260229 and searching it.

The document that does address it is on the same Selank product page, and finding it is the most practically useful thing in this article. The certificate for batch 29-05260628, certified 2 June 2026 by Kovera Labs, does include a bacterial endotoxin analysis by kinetic chromogenic LAL to USP Chapter 85, reporting under 0.20 endotoxin units per millilitre against an acceptance limit of 0.5, plus a rapid sterility screen and a heavy metals panel by ICP-MS.

The fair reading is that this is a batch question rather than a product question. The vendor's Semax listing shows the same February-to-June change, so the panel moved across the catalogue rather than favouring one compound. The trap is that the clickable link on a product page is often the older, thinner PDF while the fuller document sits beside it as an image. Read every certificate on the page, ask which batch is being shipped, and treat the question as open until you have that batch's document.

On price and transparency the listing does well. Selank 10 mg is $47.50, or $23.75 with the code PEPTIDEDECK, which is $2.38 per milligram. Quantity purchases of three, five or ten take 3, 5 or 10 percent off list instead, and nothing published says the code stacks with them.

On logistics it does well too. A published same-day dispatch cutoff of 2pm CST is only possible with stock already in a US warehouse, which matters for a peptide that would otherwise spend weeks in a customs queue at an unmonitored temperature.

On testing scope it depends entirely on which batch you are sent, in the way set out above, and we have run no analysis ourselves: everything here comes from the vendor's own documents.

And on what this channel structurally cannot offer: no prescriber, no pharmacist checking the preparation, no patient label, no follow-up, no recall that reaches your address. If those absences are decisive, the checklist has not failed; it has pointed you at a channel that for Selank does not exist. Our piece on NAD+, where a compounded prescription route genuinely does exist, shows the alternative when a substance clears the test Selank fails.

Everything above compresses into seven checks you can run from a browser tab before spending anything. Read the third column first: it turns a standard into a decision.

No supplier here clears every line, including the one we link, and a page claiming otherwise is selling rather than assessing. The point is to know which gaps you accept deliberately rather than discover after the vial arrives. Our scam checker runs the same logic against any specific offer.

Selank where to buy has one real answer and several fake ones. The fake ones imply a clinic or a compounding pharmacy might supply it if you ask the right way. They cannot, for the statutory reason set out at the top.

The real answer is a research vial from a supplier vetted on documents rather than design: a lot-specific certificate, purity shown as a chromatogram, a measured mass near 751.43, and something addressing endotoxins. Ascension clears all four on its June batch and only the first three on its February one, so the answer turns on which batch you are sent.

For how the channels compare before you commit, our channel-by-channel comparison for Selank sets them side by side, and our methodology covers how we assess the regulated side.